The synergistic effect of exposure to alcohol, tobacco smoke and other risk factors for age-related macular degeneration

2013 ◽  
Vol 28 (5) ◽  
pp. 445-446 ◽  
Author(s):  
Giuseppe La Torre ◽  
Elena Pacella ◽  
Rosella Saulle ◽  
Guglielmo Giraldi ◽  
Fernanda Pacella ◽  
...  
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maiko Maruyama-Inoue ◽  
Tatsuya Inoue ◽  
Shaheeda Mohamed ◽  
Yoko Kitajima ◽  
Shoko Ikeda ◽  
...  

AbstractThe purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent ≥ 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP ≥ 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 ± 26.5 months. History of glaucoma (p = 0.021; odds ratio, 5.85), treatment modality (p = 0.019; odds ratio, 6.32), and total number of injections (p = 0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.


2021 ◽  
Vol 22 (3) ◽  
pp. 1170
Author(s):  
Arunbalaji Pugazhendhi ◽  
Margaret Hubbell ◽  
Pooja Jairam ◽  
Balamurali Ambati

Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid, mainly affecting the elderly population causing gradual vision impairment. Risk factors such as age, race, genetics, iris color, smoking, drinking, BMI, and diet all play a part in nvAMD’s progression, with anti-vascular endothelial growth factor (anti-VEGF) therapy being the mainstay of treatment. Current therapeutic advancements slow the progression of the disease but do not cure or reverse its course. Newer therapies such as gene therapies, Rho-kinase inhibitors, and levodopa offer potential new targets for treatment.


2020 ◽  
Vol 4 (7) ◽  
pp. 662-672 ◽  
Author(s):  
Usha Chakravarthy ◽  
Clare C. Bailey ◽  
Peter H. Scanlon ◽  
Martin McKibbin ◽  
Rehna S. Khan ◽  
...  

Ophthalmology ◽  
2014 ◽  
Vol 121 (9) ◽  
pp. 1766-1772 ◽  
Author(s):  
Fridbert Jonasson ◽  
Diana E. Fisher ◽  
Gudny Eiriksdottir ◽  
Sigurdur Sigurdsson ◽  
Ronald Klein ◽  
...  

2011 ◽  
Vol 152 (3) ◽  
pp. 385-395 ◽  
Author(s):  
Farzana Choudhury ◽  
Rohit Varma ◽  
Roberta McKean-Cowdin ◽  
Ronald Klein ◽  
Stanley P. Azen

Ophthalmology ◽  
2004 ◽  
Vol 111 (7) ◽  
pp. 1280-1287 ◽  
Author(s):  
Sandra C. Tomany ◽  
Jie Jin Wang ◽  
Redmer van Leeuwen ◽  
Ronald Klein ◽  
Paul Mitchell ◽  
...  

Ophthalmology ◽  
2008 ◽  
Vol 115 (8) ◽  
pp. 1376-1381.e2 ◽  
Author(s):  
Ryo Kawasaki ◽  
Jie Jin Wang ◽  
Gui-jin Ji ◽  
Bronwen Taylor ◽  
Toshihide Oizumi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document